Intravenous Infusions Plc (GHSE:IIL)
Ghana · Delayed Price · Currency is GHS 0.6400
-0.1400 (-17.95%)
At close: Aug 5, 2026
Intravenous Infusions Income Statement
Financials in millions GHS. Fiscal year is January - December.
Millions GHS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6.51 | 9.3 | 24.94 | 31.42 | 20.36 | 22.67 | |
Revenue Growth | -29.99% | -62.70% | -20.61% | 54.34% | -10.21% | 9.69% |
Cost of Revenue | 4.26 | 7.99 | 13.39 | 14.14 | 11.6 | 12.04 |
Gross Profit | 2.25 | 1.31 | 11.55 | 17.28 | 8.76 | 10.63 |
Selling, General & Admin | 6.98 | 8.71 | 10.07 | 9.96 | 11.39 | 8.86 |
Amortization of Goodwill & Intangibles | 0.01 | 0.01 | 0.01 | 0.01 | 0 | - |
Operating Expenses | 7.53 | 9.27 | 10.73 | 10.76 | 11.96 | 9.41 |
Operating Income | -5.28 | -7.96 | 0.82 | 6.52 | -3.21 | 1.23 |
Interest Expense | -0.12 | -0.11 | -0.14 | -0.72 | -0.39 | -0.15 |
Other Non Operating Income (Expenses) | -0.12 | 2.29 | -1.17 | -2.35 | 0.06 | 0.36 |
EBT Excluding Unusual Items | -5.52 | -5.78 | -0.49 | 3.44 | -3.54 | 1.43 |
Gain (Loss) on Sale of Assets | - | - | 0.01 | 0.05 | 0 | - |
Pretax Income | -5.52 | -5.78 | -0.49 | 3.49 | -3.53 | 1.43 |
Income Tax Expense | -1.09 | -1.15 | 0.16 | 0.95 | -0.02 | 0.29 |
Net Income | -4.43 | -4.63 | -0.64 | 2.54 | -3.51 | 1.15 |
Net Income to Common | -4.43 | -4.63 | -0.64 | 2.54 | -3.51 | 1.15 |
Net Income Growth | - | - | - | - | - | -20.99% |
Shares Outstanding (Basic) | 316 | 274 | 274 | 274 | 274 | 274 |
Shares Outstanding (Diluted) | 316 | 274 | 274 | 274 | 274 | 274 |
Shares Change | 15.25% | - | - | - | - | - |
EPS (Basic) | -0.01 | -0.02 | -0.00 | 0.01 | -0.01 | 0.00 |
EPS (Diluted) | -0.01 | -0.02 | -0.00 | 0.01 | -0.01 | 0.00 |
EPS Growth | - | - | - | - | - | -21.00% |
Free Cash Flow | -5.2 | -0.87 | 5.59 | 2.39 | 0.45 | -3.86 |
Free Cash Flow Per Share | -0.02 | -0.00 | 0.02 | 0.01 | 0.00 | -0.01 |
Dividend Per Share | - | - | - | 0.003 | - | - |
Dividend Growth | - | - | - | -3.78% | - | - |
Gross Margin | 34.60% | 14.07% | 46.31% | 55.01% | 43.02% | 46.91% |
Operating Margin | -81.01% | -85.52% | 3.28% | 20.74% | -15.76% | 5.42% |
Profit Margin | -68.01% | -49.78% | -2.58% | 8.10% | -17.24% | 5.06% |
Free Cash Flow Margin | -79.84% | -9.38% | 22.43% | 7.59% | 2.22% | -17.03% |
EBITDA | -4.76 | -7.41 | 1.47 | 7.31 | -2.64 | 1.76 |
EBITDA Margin | -73.08% | -79.63% | 5.89% | 23.27% | -12.98% | 7.79% |
D&A For EBITDA | 0.52 | 0.55 | 0.65 | 0.79 | 0.56 | 0.54 |
EBIT | -5.28 | -7.96 | 0.82 | 6.52 | -3.21 | 1.23 |
EBIT Margin | -81.01% | -85.52% | 3.28% | 20.74% | -15.76% | 5.42% |
Effective Tax Rate | - | - | - | 27.17% | - | 19.97% |